Physician profile
Michael Christopher Heeg
NPI 1972555142
$4,870.01
in general payments reported to CMS, 2019-2025
28 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $149 · 2021: $184 · 2022: $514 · 2023: $599 · 2024: $1,070 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Education: $82.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.37 |
| Education | $82.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $856.71 | 2019-2021 | |
| Astellas Pharma US INC | $702.58 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $541.49 | 2019-2025 | Eylea Hd |
| Abbvie INC. | $302.86 | 2022-2025 | |
| Allergan, INC. | $301.61 | 2019 | |
| Apellis Pharmaceuticals, INC. | $297.91 | 2022-2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $263.60 | 2019-2025 | |
| Genentech USA, INC. | $247.35 | 2022-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $199.89 | 2019-2025 | Rocklatan |
| Bausch & Lomb Americas INC. | $160.02 | 2023-2025 | Vyzulta, Xipere, Miebo |
| Alimera Sciences, INC. | $125.48 | 2020-2023 | Iluvien |
| Eyepoint US, INC. | $105.45 | 2019-2020 | |
| Biotissue Holdings INC. | $80.61 | 2023 | |
| Harrow Eye, LLC | $77.96 | 2025 | Iheezo, Triesence, Vevye |
| Sandoz INC. | $75.30 | 2024-2025 | Cimerli |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.57 | 2019-2022 | |
| Thea Pharma INC. | $67.80 | 2023-2025 | Iyuzeh |
| Coherus Oncology, INC. | $62.08 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $52.14 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Amgen INC. | $49.39 | 2024-2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $47.84 | 2019 | |
| Oyster Point Pharma, INC. | $41.18 | 2024-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $38.00 | 2025 | Xdemvy |
| Neurotech Pharmaceuticals, INC. | $25.14 | 2025 | |
| Shire North American Group INC | $19.93 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.76 | 2019 | |
| Horizon Therapeutics Plc | $18.23 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $18.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heeg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.